|
|
| Internet Indicators | Tech Metrics | Economic Indicators | Financial Markets | Industry Insights | Business Metrics | Global Monitor |
| Metrics 2.0» Industry Insights» Healthcare/Pharma: |
With
the new Democratic Congress promising to lower
health care costs, generic drug makers take on
brand-name rivals
to level the playing field, reports
AP. Here are some key metrics and stats
on the generic drugs market:
Continue reading... "$22B US Generic Drugs Industry by the Numbers" »
U.S.
health care costs are set to double over the next 10 years to $4.1
trillion annually, or 1 dollar of every 5 dollars spent, according to a
study by Centers for Medicare & Medicaid Services, published today in
the Web edition of the journal Health Affairs.
Global
pharmaceuticals sales through retail pharmacies increased 5% to $386.23
billion in 13 key markets in the 12-month period from November 2005 through to November 2006,
according to IMS Retail Drug Monitor.
Continue reading... "Global Pharmaceutical Sales Grew 5% to $386 billion; U.S. Share $196 billion" »
U.S.
regulators approved 18 new drugs in 2006, close to an eight-year low, as
the number of medicines recommended for sale in 2006 and 2005 dropped from
the annual average of 26 drugs recorded in the previous six years,
according to U.S. data.
Continue reading... "U.S. New Drug Approvals at 8 Year Low; R&D Spend Hits $40B" »
Lipitor,
the world's biggest-selling drug at $12.2 billion last year, is one of six
Pfizer products losing patent protection by 2011. Pfizer's (PFE)
shares fell as much as 15%, wiping nearly $30 billion off the company's
market value, after the world's biggest drugmaker ended development of its
cholesterol pill torcetrapib designed to replace Lipitor when its patent
expires.
Within
the next 25 years, AIDS is set to join heart disease and stroke as the top
three causes of death worldwide, according to a new report in the Public
Library of Science's Medicine journal. AIDS is currently ranked fourth
behind heart disease, stroke, and respiratory infections.
IMS
Health reported $379.29 billion
in drug sales through retail pharmacies in 13 key markets in the 12-month
period from August 2005 through to August 2006, a 5% growth from year
ago.
Sales in the top five European markets showed a 4% constant exchange growth. North America posted a 6% sales growth at $204.85 billion in sales in the 12 months to August. The key therapy growth area for North America was the cytostatics group with a 15% growth at constant exchange. Japan's overall growth at constant exchange was 2%, with $57.14 billion sales in the 12 months to August 2006.
Continue reading... "Retail Pharma Sales Grew 5% to Over $379 billion Annual Rate" »
California's
biomedical industry is the second largest contributor to its high
technology economy, second only to computer consulting and programming, according
to a report by the California Healthcare Institute (CHI) and
PricewaterhouseCoopers.California biomedical industry accounted for $62 billion in revenue in the state last year.
Continue reading... "California Leads World in Biomedical with $62B in Revenue" »
The founding of Genentech in April 1976 is considered the birth of U.S. biotech industry. Revenues of U.S. biotech firms topped $50 billion last year, up almost 16%, double the 8% growth rate of the traditional drug makers ($600B global pharma sales in 2005). Here are Some revealing stats on the U.S Biotech industry:
